23:08 , Nov 28, 2018 |  BC Innovations  |  Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
21:22 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Clearing chemistry

A new study has discovered an in vivo use of click chemistry that can rapidly clear drugs from circulation in case of emergency. Although it raises the possibility of a universal safety switch, its adoption...
21:22 , Nov 18, 2016 |  BC Week In Review  |  Company News

Scripps Research Institute, BlinkBio deal

Scripps granted BlinkBio an option to exclusively license Dual Variable Domain-Fab (DVD-Fab) technology, which the biotech will use to develop Tunable Drug Conjugates (TDCs), initially to treat cancer. DVD-Fab consists of engineered antibody fragments that...
07:00 , Aug 25, 2016 |  BC Innovations  |  Emerging Company Profile

Fast and to the point

Shasqi Inc. is developing a drug delivery platform for safe targeting to tumors, based on "bioorthoganol chemistry," in which a pair of biologically inert molecules only react with each other and not the body's cells....
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

BlinkBio, J&J deal

BlinkBio partnered with Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit to accelerate development of BlinkBio’s lead compounds targeting the inhibition of protein-protein interactions (PPIs) for v-myc myelocytomatosis viral oncogene homolog ( MYC ; c-Myc )-related...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Financial News

Coferon completes venture financing

Coferon Inc. , New York, N.Y.   Business: Drug delivery   Date completed: 7/16/12   Type: Venture financing   Raised: $12 million   Investors: Hatteras Venture Partners; MedImmune Ventures; Ascent Biomedical Ventures  ...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Coferon management update

Coferon Inc. , New York, N.Y.   Business: Drug delivery   Transitioned: Colin Goddard to chairman and CEO from part-time executive chairman, formerly CEO of OSI Pharmaceuticals Inc. , which Astellas Pharma Inc. acquired  ...
00:11 , Jul 17, 2012 |  BC Extra  |  Financial News

Coferon raises $12M in series B

Coferon Inc. (New York, N.Y.) raised $12 million in a series B round from new investors Hatteras Venture Partners; MedImmune Ventures; and Ascent Biomedical Ventures. Coferon uses bioorthogonal linker chemistry to deliver therapeutics that self-assemble...
07:00 , Jul 16, 2012 |  BioCentury  |  Emerging Company Profile

Coferon: Some assembly required

Rather than trying to make ever smaller molecules that retain activity against complex targets, Coferon Inc. is using a bioorthogonal linker technology to deliver two halves of a therapeutic that self-assemble on the target after...
08:00 , Jan 12, 2012 |  BC Innovations  |  Strategy

A conversation with Laurie Glimcher

As Laurie Glimcher was preparing to take over as dean of Weill Cornell Medical College in New York City, SciBX caught up with her to discuss her views on research priorities for academic medical centers,...